Skip to main content
SpringerLink
Log in

Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications

  • Published:
Science and Engineering Ethics Aims and scope Submit manuscript

Abstract

Pharmaceutical companies fund the bulk of clinical research that is carried out on medications. Poor outcomes from these studies can have negative effects on sales of medicines. Previous research has shown that company funded research is much more likely to yield positive outcomes than research with any other sponsorship. The aim of this article is to investigate the possible ways in which bias can be introduced into research outcomes by drawing on concrete examples from the published literature. Poorer methodology in industry-funded research is not likely to account for the biases seen. Biases are introduced through a variety of measures including the choice of comparator agents, multiple publication of positive trials and non-publication of negative trials, reinterpreting data submitted to regulatory agencies, discordance between results and conclusions, conflict-of-interest leading to more positive conclusions, ghostwriting and the use of “seeding” trials. Thus far, efforts to contain bias have largely focused on more stringent rules regarding conflict-of-interest (COI) and clinical trial registries. There is no evidence that any measures that have been taken so far have stopped the biasing of clinical research and it’s not clear that they have even slowed down the process. Economic theory predicts that firms will try to bias the evidence base wherever its benefits exceed its costs. The examples given here confirm what theory predicts. What will be needed to curb and ultimately stop the bias that we have seen is a paradigm change in the way that we treat the relationship between pharmaceutical companies and the conduct and reporting of clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • AMSA PharmFree Scorecard 2009. (2009). Executive summary updated. http://amsascorecard.org/executive-summary. Accessed 26 Sept 2010.

  • Andersen, M., Ktragstrup, J., & Søndergaard, J. (2006). How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA, 295, 2759–2764.

    Article  Google Scholar 

  • Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. New York: Random House.

    Google Scholar 

  • Austin, P. C., Mamdani, M. M., Tu, K., & Jaakkimainen, L. (2003). Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women’s Health Initiative Study. JAMA, 289, 3241–3242.

    Article  Google Scholar 

  • Baker, D. (2008). The benefits and savings from publicly funded clinical trials of prescription drugs. International Journal of Health Services, 38, 731–750.

    Article  Google Scholar 

  • Bell, C. M., Urbach, D. R., Ray, J. G., Bayoumi, A., Rosen, A. B., Greenberg, D., et al. (2006). Bias in published cost effectiveness studies: Systematic review. BMJ, 332, 699–703.

    Article  Google Scholar 

  • Bero, L., Oostvogel, F., Bacchetti, P., & Lee, K. (2007). Factors associated with findings of published trials of drug–drug comparisons: Why some statins appear more efficacious than others. PLoS Medicine, 4, e184.

    Article  Google Scholar 

  • Bero, L. A., & Rennie, D. (1996). Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care, 12, 209–237.

    Article  Google Scholar 

  • Campbell, E. G., Weissman, J. S., Ehringhaus, S., Rao, S. R., Moy, B., Feibelmann, S., et al. (2007). Institutional academic–industry relationships. JAMA, 298, 1779–1786.

    Article  Google Scholar 

  • Cooper, R. J., Gupta, M., Wilkes, M. S., & Hoffman, J. R. (2006). Conflict of interest disclosure policies and practices in peer-reviewed biomedical journals. Journal of General Internal Medicine, 21, 1248–1252.

    Article  Google Scholar 

  • Dembner, A. (2002). Report raps drug firms' 'post-approval studies. Boston Globe.

  • DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010). Trends in risks associated with new drug development: Success rates for investigational drugs. Clinical Pharmacology and Therapeutics, 87, 272–277.

    Article  Google Scholar 

  • Djulbegovic, B., Cantor, A., & Clarke, M. (2003). The importance of preservation of the ethical principle of equipoise in the design of clinical trials: Relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Accountability in Research, 10, 301–315.

    Article  Google Scholar 

  • Drazen, J. M., de Leeuw, P. W., Laine, C., Mulrow, C., DeAngelis, C. D., Frizelle, F. A., et al. (2010). Toward more uniform conflict disclosures—the updated ICJME conflict of interest reporting forms. New England Journal of Medicine, 363, 188–189.

    Article  Google Scholar 

  • Dunbar, C. E., & Tallman, M. S. (2009). ‘Ghostbusting’ at blood. Blood, 113, 502–503.

    Article  Google Scholar 

  • Finkelstein, S., & Temin, P. (2008). Reasonable Rx: Solving the drug price crisis. Upper Saddle River: FT Press.

    Google Scholar 

  • Franco, O. H., Peeters, A., Looman, C. W. N., & Bonneux, L. (2005). Cost effectiveness of statins in coronary heart disease. Journal of Epidemiology and Community Health, 59, 927–933.

    Article  Google Scholar 

  • Friedman, L. S., & Richter, E. D. (2004). Relationship between conflicts of interest and research results. Journal of General Internal Medicine, 19, 51–56.

    Article  Google Scholar 

  • Fries, J. F., & Krishnan, E. (2004). Equipoise, design bias, and randomized controlled trials: The elusive ethics of new drug development. Arthritis Research and Therapy, 6, R250–R255.

    Article  Google Scholar 

  • Fugh-Berman, A. (2005). The corporate coauthor. Journal of General Internal Medicine, 20, 546–548.

    Article  Google Scholar 

  • Fugh-Berman, A. (2010). The haunting of medical journals: How ghostwriting sold “HRT”. PLoS Medicine, 7(9), e1000335.

    Article  Google Scholar 

  • Goozner, M. (2004). Unrevealed: Non-disclosure of conflicts of interest in four medical and scientific journals. Washington, DC: Center for Science in the Public Interest.

    Google Scholar 

  • Gøtzsche, P. C. (1989). Multiple publication of reports of drug trials. European Journal of Clinical Pharmacology, 36, 429–432.

    Article  Google Scholar 

  • Hartmann, M., Knoth, H., Schulz, D., & Knoth, S. (2003). Industry-sponsored economic studies in oncology vs. studies sponsored by nonprofit organisations. British Journal of Cancer, 89, 1405–1408.

    Article  Google Scholar 

  • Healy, D., & Cattell, D. (2003). Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 183, 22–27.

    Article  Google Scholar 

  • Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry, 163, 185–194.

    Article  Google Scholar 

  • Hersh, A. L., Stefanick, M. L., & Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 291, 47–53.

    Article  Google Scholar 

  • Hill, K. P., Ross, J. S., Egilman, D. S., & Krumholz, H. M. (2008). The ADVANTAGE seeding trial: A review of internal documents. Annals of Internal Medicine, 149, 251–258.

    Google Scholar 

  • Hirsch, L. J. (2009). Conflicts of interest, authorship, and disclosures in industry-related scientific publications: The tort bar and editorial oversight of medical journals. Mayo Clinic Proceedings, 84, 811–821.

    Article  Google Scholar 

  • Hole, O. P., Winther, F. Ø., & Straume, B. (2001). Clinical research: The influence of the pharmaceutical industry. European Journal of Clinical Pharmacology, 56, 851–853.

    Article  Google Scholar 

  • Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280, 605–613.

    Article  Google Scholar 

  • Huston, P., & Moher, D. (1996). Redundancy, disaggregation, and the integrity of medical research. Lancet, 347, 1024–1026.

    Article  Google Scholar 

  • Jagsi, R., Sheets, N., Jankovic, A., Motomura, A. R., Amarnath, S., & Ubel, P. A. (2009). Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research. Cancer, 115, 2783–2791.

    Article  Google Scholar 

  • Johansen, H. K., & Gotzsche, P. C. (1999). Problems in the design and reporting of trials of antifungal agents encountered during meta-analyses. JAMA, 282, 1752–1759.

    Article  Google Scholar 

  • Jørgensen, A. W., Maric, K. L., Tendal, B., Faurschou, A., & Gøtzsche, P. C. (2008). Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions. BMC Medical Research Methodology, 8, 60.

    Article  Google Scholar 

  • Katz, D., Caplan, A. L., & Merz, J. F. (2003). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics, 3, 39–46.

    Article  Google Scholar 

  • Kjaergard, L. L., & Als-Nielsen, B. (2002). Association between competing interests and authors’ conclusions: Epidemiological study of randomised clinical trials published in the BMJ. BMJ, 325, 249.

    Article  Google Scholar 

  • Lacasse, J. R., & Leo, J. (2010). Ghostwriting at elite academic medical centers in the United States. PLoS Medicine, 7, e1000230.

    Article  Google Scholar 

  • Lewis, T., Reichman, J., & So, A. (2007). The case for public funding and public oversight of clinical trials. Economists’ Voice, 4(1), 1–4.

    Google Scholar 

  • Lexchin, J., Bero, L., Djubegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsored research: Evidence for a systematic bias. BMJ, 326, 1167–1170.

    Article  Google Scholar 

  • Lexchin, J., Sekeres, M., Gold, J., Ferris, L. E., Kalkar, S. R., Wu, W., et al. (2008). National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers. Journal of General Internal Medicine, 23, 1896–1903.

    Article  Google Scholar 

  • Light, D. W. (2006). Basic research funds to discover important new drugs: Who contributes how much? In M. A. Burke & A. de Francisco (Eds.), Monitoring financial flows for health research 2005: Behind the global numbers (pp. 29–43). Geneva: Global Fund for Health Research.

    Google Scholar 

  • Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003). Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ, 326, 1171–1173.

    Article  Google Scholar 

  • Miners, A. H., Garau, M., Fidan, D., & Fischer, A. J. (2005). Comparing estimates of cost effectiveness submitted to the National Institute for Cliinical Excellence (NICE) by different organisations: retrospective study. BMJ, 330, 65–69.

    Article  Google Scholar 

  • Montgomery, J. H., Byerly, M., Carmody, T., Li, B., Miller, D. R., Varghese, F., et al. (2004). An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Controlled Clinical Trials, 25, 598–612.

    Article  Google Scholar 

  • Moses, H. I., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005). Financial anatomy of biomedical research. JAMA, 294, 1333–1342.

    Article  Google Scholar 

  • Nieto, A., Mazon, A., Pamies, R., Linana, J. J., Lanuza, A., Jiménez, F. O., et al. (2007). Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Archives of Internal Medicine, 167, 2047–2053.

    Article  Google Scholar 

  • Ninan, P. T., Poole, R. M., & Stiles, G. L. (2008). Selective publication of antidepressant trials. New England Journal of Medicine, 358, 2180.

    Article  Google Scholar 

  • Patsopoulos, N. A., Ioannidis, J. P. A., & Analatos, A. A. (2006). Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ, 332, 1061–1064.

    Article  Google Scholar 

  • Perlis, C. S., Harwood, M., & Perlis, R. H. (2005a). Extent and impact of industry sponsorship conflicts of interest in dermatology research. Journal of the American Academy of Dermatology, 52, 967–971.

    Article  Google Scholar 

  • Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005b). Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. American Journal of Psychiatry, 162, 1957–1960.

    Article  Google Scholar 

  • Psaty, B. M., & Rennie, D. (2006). Clinical trial investigators and their prescribing patterns: Another dimension to the relationship between physician investigators and the pharmaceutical industry. JAMA, 295, 2787–2789.

    Article  Google Scholar 

  • Rasmussen, M., Lee, K., & Bero, L. (2009). Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials, 10, 116.

    Article  Google Scholar 

  • Rising, K., Bacchetti, P., & Bero, L. (2008). Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. PLoS Medicine, 5, e217.

    Article  Google Scholar 

  • Rochon, P. A., Gurwitz, J. H., Simms, R. W., Fortin, P. R., Felson, D. T., Minaker, K. L., et al. (1994). A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine, 154, 157–163.

    Article  Google Scholar 

  • Rochon, P. A., Sekeres, M., Lexchin, J., Moher, D., Wu, W., Kalkar, S. R., et al. (2010). Institutional financial conflicts of interest policies at Canadian academic health science centres: A national survey. Open Medicine, 4, E134–E138.

    Google Scholar 

  • Ross, J. S., Hill, K. P., Egilman, D. S., & Krumholz, H. M. (2008). Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib ligitation. JAMA, 299, 1800–1812.

    Article  Google Scholar 

  • Safer, D. J. (2002). Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. Journal of Nervous and Mental Disease, 190, 583–592.

    Article  Google Scholar 

  • Schafer, A. (2004). Biomedical conflicts of interest: A defence of the sequestration thesis—learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics, 30, 8–24.

    Article  Google Scholar 

  • Sekeres, M., Gold, J. L., Chan, A.-W., Lexchin, J., Moher, D., Van Laethem, M. L. P., et al. (2008). Poor reporting of scientific leadership information in clinical trial registers. PLoS One, 3, e1610.

    Article  Google Scholar 

  • Sismondo, S. (2008a). How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science and Medicine, 66, 1909–1914.

    Article  Google Scholar 

  • Sismondo, S. (2008b). Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials, 29, 109–113.

    Article  Google Scholar 

  • Spielmans, G. I., Biehn, T. L., & Sawrey, D. L. (2010). A case study of salami slicing: Pooled analyses of duloxetine for depression. Psychotherapy and Psychosomatics, 79, 97–106.

    Article  Google Scholar 

  • Stossel, T. P. (2005). Regulating academic–industrial research relationships—solving problems or stifling progress? New England Journal of Medicine, 353, 1060–1065.

    Article  Google Scholar 

  • Tramèr, M. R., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (1997). Impact of covert duplicate publication on meta-analysis: A case study. BMJ, 315, 635–640.

    Article  Google Scholar 

  • Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252–260.

    Article  Google Scholar 

  • van McCrary, S., Anderson, C. B., Jakovljevic, J., Khan, T., McCullough, L. B., Wray, N. P., et al. (2000). A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine, 343, 1621–1626.

    Article  Google Scholar 

  • Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363, 1341–1345.

    Article  Google Scholar 

  • Wood, A. J. J. (2009). Progress and deficiencies in the registration of clinical trials. New England Journal of Medicine, 360, 824–830.

    Article  Google Scholar 

  • Writing Group for the Women’s Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288, 321–333.

    Article  Google Scholar 

  • Wyatt, J. (1991). Use and sources of medical knowledge. Lancet, 338, 1368–1373.

    Article  Google Scholar 

  • Yank, V., Rennie, D., & Bero, L. A. (2007). Financial ties and concordance between results and conclusions in meta-analyses: Retrospective cohort study. BMJ, 335, 1202–1205.

    Article  Google Scholar 

  • Zarin, D. A., Tse, T., & Ide, N. C. (2005). Trial registration at ClinicalTrials.gov between May and October 2005. New England Journal of Medicine, 353, 2779–2787.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Health Policy and Management, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada

    Joel Lexchin

  2. University Health Network, Toronto, ON, Canada

    Joel Lexchin

  3. Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada

    Joel Lexchin

Authors
  1. Joel Lexchin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Lexchin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lexchin, J. Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. Sci Eng Ethics 18, 247–261 (2012). https://doi.org/10.1007/s11948-011-9265-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11948-011-9265-3

Keywords

Search

Navigation